Use of trastuzumab as a HER2 inhibitor targeted therapy among select patients with mild asymptomatic cardiomyopathy (LVEF 40–53%) seems to be safe with close monitoring of cardiotoxicity and appropriate cardioprotective treatments (BB, ACE-I, /ARB, spironolactone). This evidence concerns the gene ERBB2 and cardiomyopathy.